SCHEMBL2614552

SCHEMBL2614552

COc1cc2c(Nc3ccc4c(C(=O)NC5CC5)cccc4c3)ccnc2cc1OCC1(N)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.61
AURKB Q96GD4 8/20 0.61
FLT1 P17948 3/20 0.61
LYN P07948 3/20 0.61
FGFR1 P11362 2/20 0.61
FGFR2 P21802 2/20 0.61
FLT4 P35916 2/20 0.61
PDXK O00764 1/20 0.61
RIPK2 O43353 1/20 0.61
RET P07949 1/20 0.61
PDGFRB P09619 1/20 0.61
FGFR3 P22607 1/20 0.61
DDR1 Q08345 1/20 0.61
DDR2 Q16832 1/20 0.61
AURKA O14965 11/20 0.59
TEK Q02763 11/20 0.59
MET P08581 10/20 0.59
LCK P06239 8/20 0.59
ABL1 P00519 1/20 0.59
FGR P09769 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14069024 0.92 KDR (0.51) KDRAURKBFLT1LYNFGFR1
SCHEMBL2614561 0.91 KDR (0.74) KDRAURKBFLT1LYNFGFR1
SCHEMBL2614553 0.90 KDR (0.60) KDRAURKBFLT1LYNFGFR1
SCHEMBL2097763 0.86 KDR (0.83) KDRAURKBFLT1LYNFGFR1
SCHEMBL2614559 0.85 KDR (0.64) KDRAURKBFLT1LYNFGFR1
SCHEMBL2622081 0.84 KDR (0.61) KDRAURKBFLT1LYNFGFR1
SCHEMBL2614554 0.83 KDR (0.65) KDRAURKBFLT1LYNFGFR1
SCHEMBL14069008 0.82 KDR (0.51) KDRAURKBFLT1LYNFGFR1
SCHEMBL2614562 0.81 KDR (0.63) KDRAURKBFLT1LYNFGFR1
SCHEMBL4548961 0.80 KDR (0.73) KDRAURKBFLT1LYNFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513283-B2 Spiro substituted compounds as angiogenesis inhibitors ADVENCHEN LABORATORIES, LLC (US) 2013-08-20 US disclosed
US-20120165371-A1 SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS ADVENCHEN LABORATORIES, LLC (US) 2012-06-28 US disclosed
US-8163923-B2 Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases ADVENCHEN LABORATORIES, LLC (US) 2012-04-24 US disclosed
US-8163923-B2 Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases ADVENCHEN LABORATORIES, LLC (US) 2012-04-24 US disclosed
US-20080227812-A1 Spiro Substituted Compounds As Angiogenesis Inhibitors ADVENCHEN LABORATORIES, LLC 2008-09-18 US disclosed
US-20080227812-A1 Spiro Substituted Compounds As Angiogenesis Inhibitors ADVENCHEN LABORATORIES, LLC 2008-09-18 US disclosed
WO-2008112408-A1 SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS ADVENCHEN LABORATORIES, LLC (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165371-A1 SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS TEK, KDR, TIE1 KDR 2/4885AURKB 247/4885FLT1 4/4885
US-20080227812-A1 Spiro Substituted Compounds As Angiogenesis Inhibitors TEK, KDR, TIE1 KDR 2/4885AURKB 247/4885FLT1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.